Clinical Trials Logo

Filter by:
NCT ID: NCT01076621 Completed - Menopause Clinical Trials

Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 Months

Start date: May 2010
Phase: N/A
Study type: Observational

This study is conducted in Europe. The primary aim of this observational study is to investigate the occurrence of bleeding in women taking 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) for 12 months.

NCT ID: NCT01076374 Completed - Arrhythmia Clinical Trials

MEDTRONIC ADAPTA, VERSA AND SENSIA nEw3 POST APPROVAL STUDY

Start date: July 2008
Phase:
Study type: Observational

The primary purpose of this study is to assess the long term reliability of the Medtronic Adapta®/Sensia™/Versa™ platform of devices. This study is required by FDA as a condition of approval of nEw3 devices. Patients will be followed for 5 years after implant. This study utilizes data collected from the System Longevity Study (SLS).

NCT ID: NCT01076361 Completed - Heart Failure Clinical Trials

Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study

4968
Start date: September 1999
Phase: N/A
Study type: Observational [Patient Registry]

The Medtronic CapSure Epi Lead Post-approval Study will assess long-term safety of the 4968 lead. This study is part of the Medtronic System Longevity Study.

NCT ID: NCT01076348 Completed - Heart Failure Clinical Trials

Model 4965 Post-Approval Study

Start date: September 1996
Phase:
Study type: Observational

Safety and effectiveness will be summarized for the model 4965 lead. This study was conducted within Medtronic's System Longevity Study (SLS).

NCT ID: NCT01075659 Completed - Smoking Cessation Clinical Trials

Early Effects of a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge

Start date: February 2010
Phase: Phase 2
Study type: Interventional

A comparison of two products for oral nicotine replacement with respect to relief of urges to smoke after single doses of nicotine.

NCT ID: NCT01075282 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)

AWARD-2
Start date: February 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes. Participants must also be taking metformin and glimepiride.

NCT ID: NCT01074944 Completed - Gaucher Disease Clinical Trials

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)

Start date: June 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy and safety of once daily (QD) versus twice daily (BID) dosing of eliglustat tartrate (Genz-112638) in patients with Gaucher disease type 1 who have demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638). The secondary objective is to evaluate the pharmacokinetics (PK) of Genz-99067 when eliglustat tartrate (Genz-112638) is administered QD and BID in patients with Gaucher disease type 1 who have demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638).

NCT ID: NCT01072422 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Smoking Cessation in Primary Health Care Patients With Obstructive Pulmonary Disease

Start date: March 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if an assessment protocol that measures the need for support with smoking cessation and that will be administered by primary health care nurses helps patients with obstructive pulmonary disease (COPD) quit smoking.

NCT ID: NCT01072240 Completed - Clinical trials for Lymphocytic Leukemia, Chronic

An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia

Start date: September 2009
Phase: N/A
Study type: Observational

This observational study will monitor and register infusion-related adverse events and their handling in patients with chronic lymphocytic leukemia on treatment with MabThera (rituximab). Data will be collected from patients receiving intravenous MabThera at a dose of 375mg/m2 in cycle 1 and 500mg/m2 in subsequent cycles at each treatment visit for up to 6 months. Target sample size is 100 patients.

NCT ID: NCT01070550 Completed - Clinical trials for Hepatitis C, Chronic

PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a)

Start date: June 2007
Phase: N/A
Study type: Observational

This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) and ribavirin. Data will be collected during the treatment period (24 or 48 weeks) and 12 and 24 weeks after the end of treatment. Target sample size is <5000.